# Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

> **NCT02817113** · PHASE1 · TERMINATED · sponsor: **Orient Europharma Co., Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Head and Neck Neoplasms

## Interventions

- **DRUG:** NC-6004
- **DRUG:** Cetuximab
- **DRUG:** 5-FU

## Key facts

- **NCT ID:** NCT02817113
- **Lead sponsor:** Orient Europharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Strategy change
- **Last updated:** 2021-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02817113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02817113, "Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02817113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*